Comments on ICER’s Draft Evidence Report on Beta-Amyloid Antibodies for Early Alzheimer’s Disease

ICER released its draft evidence report on beta-amyloid antibodies for early Alzheimer’s disease.

ICER has redefined the scope of this review multiple times since it was first announced over a year ago. Multiple edits to both the timeline and the interventions of interest make meaningful participation in the process difficult.

Read Comments

Categorized in: